Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Voyager Therapeutics

EU flag

New cancer meds and drug extensions top CHMP recommendations

Drugs for rare disease, oncology and diabetes top regulator’s endorsements

- PMLiVE

Novartis and GSK complete oncology and vaccines swap

Follows Swiss company's decision to divest its BRAF and MEK inhibitors to Array BioPharma

- PMLiVE

Novartis gets OK for panobinostat in myeloma

First HDAC to receive positive FDA review

- PMLiVE

Novartis’ heart failure drug could get FDA nod in summer

Some predicting sales of $5bn within four years for LCZ696

- PMLiVE

Personalised cancer medicines showcased in BBC investigation

Panorama looked at cutting-edge science and the new generation of oncology drugs

Novartis building

Novartis’ Japanese subsidiary threatened with suspension

Company failed to report more than 3,200 adverse events among patients taking its drugs

Novartis building

Novartis sees first benefits from efficiency drive

Made $1.6bn in savings in 2014

- PMLiVE

Novartis begins sale talks for Horsham, UK site

Enters negotiations with the University of Brighton

- PMLiVE

Novartis launches another localised NHS eye service in UK

Will provide specialised care to people of Coventry

- PMLiVE

Novartis’ Cosentyx cleared for psoriasis in Europe

First of the IL-17 inhibitor classof drug to receive European approval

- PMLiVE

Novartis forms digital health investment company with Qualcomm

Expands work with Tricorder prize firm to develop 'beyond-the-pill' initiatives

Novartis building

Novartis files COPD combo in US

QVA149 combines long-acting beta agonist with long-acting muscarinic antagonist

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links